Our Science and Pipeline

Science
Pipeline

Latest news

Jul 16, 2026

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Read more
May 12, 2026

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Read more
May 07, 2026

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Read more

More news

Back to Top
X